Drug General Information (ID: DDI5IXCBTP)
Drug Name			Tositumomab (I-131)		Drug Info		Deoxycholic acid		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Therapeutic Radiopharmaceuticals				Cytolytic Agents

Mechanism of Tositumomab (I-131)-Deoxycholic acid Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Tositumomab (I-131)				Deoxycholic acid
Mechanism		Risk of bleeding Thrombolytic agent				Risk of submental hematoma or bruising
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Deoxycholic acid and Tositumomab (I-131)

Recommended Action
Management		Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.

References
1	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
2	Product Information. Kybella (deoxycholic acid). Kythera Biopharmaceuticals, Inc., Westlake Village, CA.